temozolomide has been researched along with bibw 2992 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S | 1 |
| Alshami, J; Cseh, A; Gibson, N; Guiot, MC; Kavan, P; Muanza, T; Owen, S; Reardon, DA; Solca, F | 1 |
| Armenia, E; Aurilio, C; Barbarisi, A; Barbarisi, M; Botti, G; De Sena, G; Iaffaioli, RV; Libutti, M; Maurea, N; Quagliariello, V | 1 |
| Batra, SK; Gorantla, S; Jain, M; Macha, MA; Mallya, K; Nimmakayala, RK; Ponnusamy, MP; Rachagani, S; Shonka, N; Siddiqui, JA; Vengoji, R | 1 |
| Bharia, S; Burma, S; Damanwalla, Z; Gerber, DE; Gong, K; Guo, G; Habib, AA; Hatanpaa, KJ; Mickey, BE; Mukherjee, B; Pan, E; Panchani, N; Patel, TR; Puliyappadamba, VT; Sarkaria, JN; Zhao, D | 1 |
| Akiyoshi, H; Ichikawa, T; Inoue, M; Kamishina, H; Kurozumi, K; Matsumoto, Y; Nakamoto, Y; Noguchi, S | 1 |
| Bender, S; Brada, M; Cseh, A; Gattamaneni, R; Harris, F; James, A; Jefferies, S; McBain, C; Pemberton, K; Saran, F; Schaible, J; Welsh, L | 1 |
2 trial(s) available for temozolomide and bibw 2992
| Article | Year |
|---|---|
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2015 |
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcome | 2021 |
5 other study(ies) available for temozolomide and bibw 2992
| Article | Year |
|---|---|
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2015 |
Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells.
Topics: Afatinib; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Boswellia; Cardiotonic Agents; Cell Line, Tumor; Chemokine CXCL12; ErbB Receptors; Glioblastoma; Humans; Interleukin-6; Interleukin-8; Leukotriene B4; Lipid Peroxidation; Myocytes, Cardiac; Reactive Oxygen Species; Temozolomide; Transcription Factor RelA; Triterpenes | 2019 |
Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Neoplastic Stem Cells; Proto-Oncogene Proteins c-met; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2019 |
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Temozolomide; Thalidomide; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2019 |
The NRG3/ERBB4 signaling cascade as a novel therapeutic target for canine glioma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dog Diseases; Dogs; Gene Expression Regulation, Neoplastic; Glioma; MicroRNAs; Neuregulins; Receptor, ErbB-4; Temozolomide | 2021 |